Inspira Technologies completes clinical study for HYLA blood sensor

Inspira Technologies (IINN) OXY announced the completion of the clinical study for its HYLA, non-invasive blood sensor, toward regulatory submission and future commercialization. Based on the clinical trial results and ongoing lab tests, showing between 95% to 99% accuracy across measured parameters, Inspira is soon entering the final validation and verification stage ahead of planned regulatory submission. Dagi Ben-Noon, Chief Executive Officer of Inspira Technologies, stated: “The system is performing at exceptional accuracy levels in our testing – between 95 and 99 percent across the board. These results reinforce HYLA’s position as a disruptive, non-invasive solution for real-time blood monitoring. We are now entering the final phase before submitting for regulatory approval.”